Literature DB >> 15980392

Efficacy of nebulized liposomal amphotericin B in treatment of experimental pulmonary aspergillosis.

Joan Gavaldà1, María-Teresa Martín, Pedro López, Xavier Gomis, José-Luís Ramírez, Dolors Rodríguez, Oscar Len, Yolanda Puigfel, Isabel Ruíz, Albert Pahissa.   

Abstract

The efficacy of therapeutic aerosolized amphotericin B (AMB) was studied in a steroid-immunosuppressed murine model of invasive pulmonary aspergillosis. Nebulized liposomal AMB can be a valid approach to the treatment of this infection, with subjects showing significantly improved survival relative to that of subjects given intravenous deoxycholate AMB, as well as lower lung weights and pulmonary glucosamine levels.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15980392      PMCID： PMC1168712          DOI： 10.1128/AAC.49.7.3028-3030.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  19 in total

Review 1.  British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections.

Authors:  David W Denning; Christopher C Kibbler; Rosemary A Barnes
Journal:  Lancet Infect Dis       Date:  2003-04       Impact factor: 25.071

2.  Measurement of the respiratory volumes of laboratory animals.

Authors:  A C GUYTON
Journal:  Am J Physiol       Date:  1947-07-01

Review 3.  Invasive aspergillosis.

Authors:  D W Denning
Journal:  Clin Infect Dis       Date:  1998-04       Impact factor: 9.079

4.  Efficacy of aerosolized amphotericin B desoxycholate and liposomal amphotericin B in the treatment of invasive pulmonary aspergillosis in severely immunocompromised rats.

Authors:  E J Ruijgrok; A G Vulto; E W Van Etten
Journal:  J Antimicrob Chemother       Date:  2001-07       Impact factor: 5.790

5.  Efficacy of prophylactic aerosol amphotericin B lipid complex in a rat model of pulmonary aspergillosis.

Authors:  C E Cicogna; M H White; E M Bernard; T Ishimura; M Sun; W P Tong; D Armstrong
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

Review 6.  Aspergillosis case-fatality rate: systematic review of the literature.

Authors:  S J Lin; J Schranz; S M Teutsch
Journal:  Clin Infect Dis       Date:  2001-01-26       Impact factor: 9.079

7.  The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants.

Authors:  A Minari; R Husni; R K Avery; D L Longworth; M DeCamp; M Bertin; R Schilz; N Smedira; M T Haug; A Mehta; S M Gordon
Journal:  Transpl Infect Dis       Date:  2002-12       Impact factor: 2.228

8.  Amphotericin B: time for a new "gold standard".

Authors:  Luis Ostrosky-Zeichner; Kieren A Marr; John H Rex; Stuart H Cohen
Journal:  Clin Infect Dis       Date:  2003-07-22       Impact factor: 9.079

9.  Pharmacokinetics of aerosol amphotericin B in rats.

Authors:  Y Niki; E M Bernard; H J Schmitt; W P Tong; F F Edwards; D Armstrong
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

10.  Pharmacokinetic evaluation of amphotericin B in lung tissue: lung lymph distribution after intravenous injection and airspace distribution after aerosolization and inhalation of amphotericin B.

Authors:  T Koizumi; K Kubo; T Kaneki; M Hanaoka; T Hayano; T Miyahara; K Okada; K Fujimoto; H Yamamoto; T Kobayashi; M Sekiguchi
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191
View more
  8 in total

1.  In vivo efficacy of aerosolized nanostructured itraconazole formulations for prevention of invasive pulmonary aspergillosis.

Authors:  Barbara J Hoeben; David S Burgess; Jason T McConville; Laura K Najvar; Robert L Talbert; Jay I Peters; Nathan P Wiederhold; Bradi L Frei; John R Graybill; Rosie Bocanegra; Kirk A Overhoff; Prapasri Sinswat; Keith P Johnston; Robert O Williams
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

2.  The effect of liposome encapsulation on the pharmacokinetics of recombinant secretory leukocyte protease inhibitor (rSLPI) therapy after local delivery to a guinea pig asthma model.

Authors:  Aileen Gibbons; Danielle Padilla-Carlin; Ciara Kelly; Anthony J Hickey; Clifford Taggart; Noel G McElvaney; Sally-Ann Cryan
Journal:  Pharm Res       Date:  2011-06-07       Impact factor: 4.200

Review 3.  Animal Models of Aspergillosis.

Authors:  Guillaume Desoubeaux; Carolyn Cray
Journal:  Comp Med       Date:  2018-04-02       Impact factor: 0.982

4.  Liposomes prolong the therapeutic effect of anti-asthmatic medication via pulmonary delivery.

Authors:  Xiaoyu Chen; Wenhua Huang; Blenda Chi Wong; Linlin Yin; Yuen Fan Wong; Min Xu; Zhijun Yang
Journal:  Int J Nanomedicine       Date:  2012-02-28

Review 5.  Rodent Models of Invasive Aspergillosis due to Aspergillus fumigatus: Still a Long Path toward Standardization.

Authors:  Guillaume Desoubeaux; Carolyn Cray
Journal:  Front Microbiol       Date:  2017-05-16       Impact factor: 5.640

Review 6.  Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B.

Authors:  Andreas H Groll; Bart J A Rijnders; Thomas J Walsh; Jill Adler-Moore; Russell E Lewis; Roger J M Brüggemann
Journal:  Clin Infect Dis       Date:  2019-05-02       Impact factor: 9.079

Review 7.  Inhaled Liposomal Antimicrobial Delivery in Lung Infections.

Authors:  Matteo Bassetti; Antonio Vena; Alessandro Russo; Maddalena Peghin
Journal:  Drugs       Date:  2020-09       Impact factor: 9.546

Review 8.  Inhaled Antifungal Agents for Treatment and Prophylaxis of Bronchopulmonary Invasive Mold Infections.

Authors:  Kévin Brunet; Jean-Philippe Martellosio; Frédéric Tewes; Sandrine Marchand; Blandine Rammaert
Journal:  Pharmaceutics       Date:  2022-03-14       Impact factor: 6.321
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.